GUBRA: CRO profitability surged as obesity programs advanced and GUB-UCN2 entered clinical testing – TradingView

Partnered obesity programs advanced to Phase 2, and GUB-UCN2 entered Phase 1/2a. CRO Q3 revenue grew 6% QoQ and YoY as its adjusted EBIT margin rose to 25%; 2026 CRO guidance was narrowed to 2–6% growth and a 10–13% margin.Original document: Gubra A/S [GUBRA] Slides Release — Nov. 6 2026Select market data provided by ICE Data Services. Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.Copyright © 2026, American Bankers Association. CUSIP Database provided by FactSet Research Systems Inc. All rights reserved. SEC filings and other documents provided by Quartr.© 2026 TradingView, Inc. source